Chemo and radiation for recurrent rectal cancer after prior pelvic radiation
Part of Cancer, Digestive system clinical trials.
This study looks at combining total neoadjuvant therapy (chemotherapy and radiation) for rectal cancer that has come back in the pelvis after earlier radiation. It aims to see if this treatment approach can help control the disease and improve outcomes in patients with limited spread that can potentially be removed or treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of rectal cancer that has come back in the pelvis (local recurrence) and is shown on scans like MRI, CT, or PET.
- You had radiation to the pelvic area at least 6 months ago.
- Your cancer has not spread extensively (if it has spread, it is limited and considered treatable).
- You are in generally good health (able to do daily activities without major help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
This trial tests combining standard chemoradiation with an immunotherapy drug (toripalimab) before surgery for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help remove the tumor more effectively.
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
This trial tests whether giving radiation (with or without chemo) before surgery can help people whose rectal cancer has come back in the pelvis. It aims to make the tumor removable and improve outcomes.
This trial studies a combination of SBRT (a precise kind of radiation) and an immunotherapy drug (PD-1 antibody) for people whose rectal cancer has come back in the pelvis and cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or stop it from growing.
This trial tests an “induction chemotherapy” treatment before surgery for people whose rectal cancer has come back in the local area. The goal is to shrink/control the cancer early and improve outcomes after treatment.
Hear when a new Rectal Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.